HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Pseudo von Willebrand disease — Clinical Guidelines

Overview

Pseudo von Willebrand disease (PvWD) refers to conditions that mimic von Willebrand disease (VWD) but are not due to VWF abnormalities, often presenting with bleeding symptoms without true VWF deficiencies or dysfunctions. 5 15

Diagnosis

Clinical Criteria: Tosetto bleeding score ≥ 1, family history of bleeding disorders, personal history of bleeding episodes (e.g., iron deficiency anemia). 1

Laboratory Tests:

- VWF antigen (VWF:Ag) and activity assays (VWF:RCo, VWF:CBA) to rule out true VWD. - Factor VIII levels to assess for hemophilia. - Platelet function tests to evaluate platelet function disorders. 5 20

Differential Diagnosis: Essential to distinguish from true VWD subtypes (types 1, 2, 3) using VWF propeptide ratios and multimeric structure analysis. 2

Management

First-Line Treatments:

- Desmopressin (DDAVP) for type 1 VWD; not typically indicated for PvWD unless bleeding symptoms suggest other coagulation factor deficiencies. 10 - Factor VIII concentrates for hemophilia A if underlying condition is identified.

Adjunctive Therapies:

- Platelet transfusions or agents enhancing platelet function if platelet disorders are suspected. - Fresh frozen plasma (FFP) or cryoprecipitate for comprehensive coagulation factor replacement in specific cases. 4 22

Special Populations

Pregnancy: Close monitoring and appropriate factor replacement (e.g., FFP, cryoprecipitate) to prevent postpartum hemorrhage. Management should be individualized based on underlying condition. 13 22

Pediatrics: Perioperative management requires multidisciplinary collaboration (anesthesiologist, hematologist, surgeon) to prevent bleeding complications during surgeries like adenotonsillectomy. 7 16

Elderly: Similar management principles apply, with emphasis on minimizing risks associated with factor concentrates and transfusions. 7

Key Recommendations

Utilize a composite score incorporating bleeding history, family history, and laboratory markers to differentiate PvWD from true VWD in pediatric patients. (Evidence: Moderate 1)

Employ comprehensive coagulation factor assays, including VWF propeptide ratios, to accurately classify bleeding disorders and exclude true VWD subtypes. (Evidence: Moderate 2 20)

For perioperative management in patients with suspected PvWD, especially in pediatric cases, ensure coordinated care among hematologists, anesthesiologists, and surgeons to mitigate bleeding risks. (Evidence: Expert opinion 7)

References

1 Malec LM, Moore CG, Bennett CM, Yee DL, Kerlin BA, Witmer CM et al.. Validation Study of the Composite Score to Identify Von Willebrand Disease in Children. Journal of pediatric hematology/oncology 2016. link 2 Haberichter SL. VWF propeptide in defining VWD subtypes. Blood 2015. link 3 Metjian AD. rVWF: treatment finally reaches the modern age. Blood 2015. link 4 Auerswald G, Bade A, Haubold K, Overberg D, Masurat S, Moorthi C. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study. Haemophilia : the official journal of the World Federation of Hemophilia 2013. link 5 Branchford BR, Di Paola J. Making a diagnosis of VWD. Hematology. American Society of Hematology. Education Program 2012. link 6 O'Brien SH. Bleeding scores: are they really useful?. Hematology. American Society of Hematology. Education Program 2012. link 7 Mazzeffi MA, Stone ME. Perioperative management of von Willebrand disease: a review for the anesthesiologist. Journal of clinical anesthesia 2011. link 8 Maquoi I, Bonhomme V, Born JD, Dresse MF, Ronge-Collard E, Minon JM et al.. Perioperative management of a child with von Willebrand disease undergoing surgical repair of craniosynostosis: looking at unusual targets. Anesthesia and analgesia 2009. link 9 Favaloro EJ, Bonar R, Marsden K. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. Clinical laboratory science : journal of the American Society for Medical Technology 2008. link 10 Federici AB. Management of inherited von Willebrand disease in 2006. Seminars in thrombosis and hemostasis 2006. link 11 Kirtava A, Crudder S, Dilley A, Lally C, Evatt B. Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States. Haemophilia : the official journal of the World Federation of Hemophilia 2004. link 12 Lindahl TL, Fagerberg IH, Larsson A. A new flow cytometric method for measurement of von Willebrand factor activity. Scandinavian journal of clinical and laboratory investigation 2003. link 13 Roqué H, Funai E, Lockwood CJ. von Willebrand disease and pregnancy. The Journal of maternal-fetal medicine 2000. link9:5<257::AID-MFM1>3.0.CO;2-J) 14 Susman-Shaw A. Von Willebrand disorder. Nursing standard (Royal College of Nursing (Great Britain) : 1987) 1999. link 15 Petrini P. Acquired von Willebrand disease. Haemophilia : the official journal of the World Federation of Hemophilia 1999. link 16 Allen GC, Armfield DR, Bontempo FA, Kingsley LA, Goldstein NA, Post JC. Adenotonsillectomy in children with von Willebrand disease. Archives of otolaryngology--head & neck surgery 1999. link 17 Varon D, Lashevski I, Brenner B, Beyar R, Lanir N, Tamarin I et al.. Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. American heart journal 1998. link70248-0) 18 Kroner PA, Frey AB. Analysis of the structure and function of the von Willebrand factor A1 domain using targeted deletions and alanine-scanning mutagenesis. Biochemistry 1996. link 19 Felts TJ, Scurran BL, Karlin JM. Use of desmopressin in a patient with von Willebrand's disease undergoing podiatric surgery. Journal of the American Podiatric Medical Association 1995. link 20 Favaloro EJ, Facey D, Grispo L. Laboratory assessment of von Willebrand factor. Use of different assays can influence the diagnosis of von Willebrand's disease, dependent on differing sensitivity to sample preparation and differential recognition of high molecular weight VWF forms. American journal of clinical pathology 1995. link 21 Takahashi Y, Kalafatis M, Girma JP, Meyer D. Abnormality of the N-terminal portion of von Willebrand factor in type IIA and IIC von Willebrand disease. Thrombosis and haemostasis 1988. link 22 Sadan O, MacPhail P, Koller AB, Hofmeyr GJ. Von Willebrand's disease in pregnancy. A case report. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 1987. link 23 McCarroll DR, Lothrop SA, Dolan MC, McDonald TP. Canine von Willebrand factor expresses a multimeric composition similar to human von Willebrand factor. Experimental hematology 1987. link 24 Berndt MC, Gregory C, Kabral A, Zola H, Fournier D, Castaldi PA. Purification and preliminary characterization of the glycoprotein Ib complex in the human platelet membrane. European journal of biochemistry 1985. link 25 Warhol MJ, Sweet JM. The ultrastructural localization of von Willebrand factor in endothelial cells. The American journal of pathology 1984. link

Pseudo von Willebrand disease